Scienion US, Inc. has announced that Courtagen Life Sciences, Inc. will use SCIENION’s sciFLEXARRAYER technology to produce innovative biochips for multiplex immunoassays, and collaborate with Scienion to meet future manufacturing and market needs.
“With its novel protein immunoassay platform, QPDx® BioChip, Courtagen has brought a fantastic product to market which has already proven to be successful for biomarker analysis in a variety of applications. We are very pleased that Courtagen, with its highly experienced team, has decided to use our sciFLEXARRAYER S11 to produce these biochips”, said Dr. Holger Eickhoff, Chief Executive Officer of SCIENION AG.
Dr. Eickhoff continued, “And with our new US subsidiary SCIENION US, Inc. we are well prepared to provide great service and extend the collaboration according to future needs of our new customer.”
Courtagen Life Sciences, Inc. has developed an automated immunoassay system that consists of a self-contained array-based QPDx® BioChip and the Avantra® Q400 Biomarker Workstation.
The system provides a simple and robust solution to the need to translate proteomics discoveries into a clinical setting.
The self-contained BioChip, one step operation, and short time to results make this technology ideally suited for testing at the point of sample collection, enabling real-time application of biomarker results.
The Avantra Q400 is a compact bench top instrument suitable for space limited areas enabling multiplex biomarker analysis for research use only (RUO) at the lab bench or clinical trial site.
“We have been looking for a reliable solution for the reproducible high throughput production of spotted arrays for our QPDx® BioChips,” said Dr. Kate Sheldon, Ph.D., Director of Product Development at Courtagen.
Dr. Sheldon continued, “The SCIENION sciFLEXARRAYER S11 is able to consistently produce high quality arrays that meet our needs, and has the capacity to meet demand as our business grows.”